Kornimate/medical-research-clean huggingface dataset:
genetic research of bone morphogenetic protein receptor-ii gene in taiwanese patient with primary pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: primary pulmonary hypertension (pph) is a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason. the pulmonary artery is a blood vessel carrying oxygen-poor blood from the right ventricle (one of the heart's pumping chambers) to the lungs. in the lungs, the blood picks up oxygen, then flows to the heart's left side, where the left ventricle pumps it to the rest of the body through the aorta. in the united states, an estimated 500 to 1,000 new cases of primary pulmonary hypertension are diagnosed each year. the greatest number is reported in women between ages 20 and 40. however, men and women in all age ranges as well as very young children can develop pph. researchers have identified more than 40 bmpr2 mutations that can cause primary pulmonary hypertension. many of these mutations introduce a stop signal that halts protein production prematurely, decreasing the amount of functional bmpr2 protein. other mutations prevent the bmpr2 protein from reaching the cell surface, or alter its structure so it cannot form a complex with other proteins. it remains unclear how bmpr2 mutations cause primary pulmonary hypertension. researchers suggest that a mutation in this gene prevents cell death or promotes cell proliferation, resulting in an overgrowth of cells in the blood vessels of the lungs. cell overgrowth can narrow the diameter of the vessels, restricting blood flow and resulting in elevated blood pressure. however, it has not yet been reported regarding the genetic variants in taiwan. further details have been described in this project proposal.


Eligibility criteria:
inclusion criteria: * diagnosed as idiopathic pulmonary artery hypertension and associated family exclusion criteria: * none

Keywords: idiopathic pulmonary artery hypertension
computer-based skin aging simulation for skin cancer prevention

Conditions: Skin Aging

Summary: this pilot study is to assess the knowledge, attitudes, and practices regarding skin cancer prevention in young adults and to determine the impact of artificial intelligence-based simulation of facial skin aging on their attitudes regarding skin cancer prevention.

in young adulthood an increasing uv-exposure often starts because of the belief that tanning increases attractiveness\]. raising awareness and educating students and adults regarding practices for skin cancer prevention are critical since skin cancer is increasing rapidly worldwide. skin cancer preventive interventions for adolescents are needed to improve their motivation for sun safety behavior. this pilot study is to assess the knowledge, attitudes, and practices regarding skin cancer prevention in young adults and to determine the impact of artificial intelligence-based simulation of facial skin aging on their attitudes regarding skin cancer prevention.

Eligibility criteria:
inclusion criteria: * healthy female volunteers * written,institutional review board (irb)/ independent ethics committee (iec)-approved informed consent. exclusion criteria: * skin diseases requiring medical therapy

Keywords: skin cancer prevention skin aging simulation uv-exposure skin analysis photo system visia® photo analysis system
self treatment with an electronic device for cognitive rehabilitation in patients with subacute stroke

Conditions: Stroke; Cognitive Deficits; Computerized Rehabilitation; Computerized Device

Summary: the objective of this study is to evaluate whether the independent use of an electronic device by a patient with stroke outcomes can enhance the effectiveness of rehabilitative treatment for attentional functions compared to standard treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of ischemic or hemorrhagic stroke; * age between 18 and 90 years; * first stroke event; * time since the stroke greater than 30 days; * adequate level of comprehension; * presence of one or more of the following cognitive disorders: memory disorders; attention disorders; executive function disorders * availability of internet access at the patient's home, necessary for telemedicine procedures. exclusion criteria: * presence of other neurological conditions; * presence of pre-morbid cognitive decline; * history of psychiatric disorders; * alcohol and/or drug abuse; * presence of severe uncorrected visual impairments.

Keywords: stroke neuropsychological rehabilitation
two or five cm from pylorus during laparoscopic sleeve gastrectomy

Conditions: Morbid Obesity

Summary: the investigators compare two techniques for laparoscopic sleeve gastrectomy. in the first one the distal margin of stapling is 2 cm from the pylorus and in the second it is 6 cm away from the pylorus.


Eligibility criteria:
inclusion criteria: * morbid obese patients exclusion criteria: * contraindication to laparoscopy
high-dose chemotherapy and stem cell transplantation, in patients pet-2 positive, after 2 courses of abvd and comparison of rt versus no rt in pet-2 negative patients

Conditions: Hodgkin's Lymphoma

Summary: the purpose of this study is to define an improvement in patients: * to evaluate if patients resistant to the initial treatment for residual pet-positive masses after the first two courses of abvd (pet-2 positive), can be salvaged by early shift to high-dose chemotherapy supported by stem cell rescue * to analyse if patients achieving early complete response (pet-2 negative), can be spared the adjuvant radiotherapy on areas of initial bulky disease, at the end of the planned six courses of abvd. to answer this question, pet-2 negative patients will be randomized between radiotherapy versus no radiotherapy at the end of abvd therapy.

this study is composed by two phases: 1. a phase ii multi-centre study evaluating in patients with advanced stage hodgkin lymphoma the efficacy of an early salvage treatment with high-dose chemotherapy followed by stem cell transplantation in patients fdg-pet positive after two courses of abvd (pet-2 positive). 2. a phase iii randomised study comparing the efficacy of radiotherapy to the areas of initial bulky disease versus no further therapy in pet-2 negative patients in complete remission (pet-6 negative) at the end of six courses of abvd.

Eligibility criteria:
inclusion criteria: * histologically confirmed hodgkin's lymphoma of the classical type (nodular lymphocyte predominance excluded). * stage iib-iv. * age 18-70. * no prior therapy for hodgkin's lymphoma * written informed consent. * ecog performance status grades 0-3 (see appendix e). * fdg-pet scan before the initiation of treatment. exclusion criteria: * prior therapy for hodgkin's lymphoma. * age less than 18 or more than 70. * other concomitant or prior malignancies, except basal cell skin carcinoma, or adequately treated carcinoma in situ of the cervix, or any cancer in complete remission for more than 5 years. * hiv infection. * pregnancy or breast-feeding. * renal failure (creatinine ≥2 times the normal value), liver failure (ast/alt or bilirubine ≥ 2.5 times the normal value) or heart failure (nyha class ≥ 2 or fev \< 45%).

Keywords: hodgkin's lymphoma abvd fdg-pet (18-fluoro-deoxy-d-glucose positron emission tomography) radiotherapy
bacterial and human biomarkers of prognostic value for severe legionnaire's disease

Conditions: Legionella

Summary: legionnaires' disease (ld) is a relatively common pneumonia in france (1200 cases/year), 98% of cases are hospitalized and 40% require intensive care unit (icu) admission. risk factors that may predispose to acquisition of ld are well known. some studies suggest that genetic factor may also enhance susceptibility to ld. the mortality rate remains high (10% to 33% in icus) despite improved diagnostic and therapeutic management of patients. few prospective studies have assessed the factors associated with ld outcomes, particularly death, and most of them involved a limited number of patients. in a multicentre cohort study, the investigators recently identified risk factors associated with higher mortality such as female sex, age, icu stay, renal failure, corticosteroid treatment and enhanced pro-inflammatory status, as assessed by higher c-reactive protein level (pmid: 22005914). other factors are suspected but their involvement has not been formally demonstrated including a high infectious bacterial load, particular virulence of legionella strain, and an in vivo selection of mutants resistant to prescribed antibiotics. disease progression is highly variable from one patient to another, and usually remains unpredictable. there are no objective criteria to predict the prognosis of these patients. the clinical course of patients with ld remains difficult to predict because no predictive biomarkers have yet been characterized and the demonstration of the presence of mutants to antibiotics in vivo has never been done. the main objective of the study is to correlate the l. pneumophila load (detected by pcr) to the clinical outcome of the ld infection. clinical severity will measured by the sofa score (sepsis -related organ failure assessment) or the pelod score (pediatric logistic organ dysfunction). secondary objectives are to identify new host and bacterial biomarkers associated with poor outcome of ld.


Eligibility criteria:
inclusion criteria: * adult patients with medical and biological signs of legionnaires' disease. * pediatric patients regardless of age but with a minimum weight of 7.5 kg with medical and biological signs of legionnaires' disease. * patient and/or his/her legal representative have reviewed the patient information/informed consent form and have given written informed consent. exclusion criteria: * none legionella pneumophila legionnaires' disease. * patients for whom respiratory secretions can't be obtained. * cases diagnosed only by serology. * outpatients.
safety of remdesivir treatment in covid-19 patients requiring hemodialysis

Conditions: Covid19; End Stage Renal Failure on Dialysis

Summary: the fda approved the antiviral drug remdesivir for use in adults for the treatment of covid-19 requiring hospitalization. there are only limited data about the safety of the drug in hemodialysed patents. chronic kidney disease is a risk factor in covid-19 for developing severe disease. the aim of our investigation is to observe the safety of remdesivir among hemodialysed patients requiring hospitalization for covid-19. we are going to compare two group's data: 1. hemodialysed covid-19 patients requiring hospitalization because of pneumonia and need of oxygen supplementation, and admitted after 12/apr/2021 - these patients received remdesivir. 2. hemodialysed covid-19 patients requiring hospitalization because of pneumonia and need of oxygen supplementation, and admitted before 12/apr/2021 - these patients did not receive remdesivir.


Eligibility criteria:
inclusion criteria: * adult patients at least 18 ys. of age * ability to understand and sign informed consent form * end stage kidney disease of any cause, requiring hemodialysis * covid-19 disease (with at least one positive sars-cov-2 rt-pcr or covid-19 antigene quick test) * radiologic evidence for pneumonia * need for oxygen supplemental oxygen exclusion criteria: * hemodynamically unstable patients (systolic blood pressure \ 120/min) * significant liver enzyme elevation at screening (asat or alat \>2.5×uln) * qtc \> 470 msec at baseline ecg (bazett formule) * need for mechanical ventilation or intensive care unit admission * limited life expectancy (\<3 months)

Keywords: remdesivir safety covid-19 hemodialysis
the combination of gnrh analogue and aromatase inhibitor in receptor positive premenopausal women with advanced breast cancer

Conditions: Advanced Breast Cancer

Summary: the combination of gnrh analogue and aromatase inhibitor in receptor positive premenopausal women with advanced breast cancer a prospective trial.

the combination of gnrh analogue and aromatase inhibitor in receptor positive premenopausal women with advanced breast cancer a prospective trial.

Eligibility criteria:
inclusion criteria: * receptor positive premenopausal women with advanced breast cancer. exclusion criteria: * any woman other than diagnosis of receptor positive premenopausal with advanced breast cancer.

Keywords: premenopausal women with advanced breast cancer
pilot study to evaluate escitalopram in obsessive-compulsive disorder

Conditions: OCD

Summary: this study will determine the safety and effectiveness of escitalopram (lexapro)in treating obsessive-compulsive disorder (ocd) symptoms.

ocd is a chronic and disabling disorder for which selective serotonin reuptake inhibitor(ssri) drugs can be effective. the purpose of this study is to evaluate the effects of an ssri, escitalopram, in ocd patients. this study will last 16 weeks and will comprise 2 phases. phase 1 is an open label in which all participants will receive daily escitalopram for 8 weeks. those who have responded to treatment at the end of the 8 weeks will be randomly assigned to either continue or discontinue their treatment for an additional 8 weeks. those who do not respond to treatment at the end of phase 1 will discontinue the study and be offered three free visits with a study clinician or referred elsewhere for treatment, based on the their preference. study visits are made at baseline, and at weeks 1, 2, 4, and 8 in phase 1 and weeks 12 and 16 in phase 2.

Eligibility criteria:
inclusion criteria: * diagnosis of ocd * a minimum score of 16 on the yale brown obsessive-compulsive scale (ybocs) at both the screening and baseline visits exclusion criteria: * lifetime history of psychosis or cognitive dysfunction due to a general medical condition or substance use * a primary diagnosis of another axis i psychiatric disorder * alcohol or other substance abuse or dependence within the last 6 months * unstable medical condition * clinically significant laboratory abnormality * failure of a previous 10-week trial of citalopram of at least 40 mg/day or escitalopram 20 mg/day * active suicidality * history of violent behavior in the past year or current risk of serious violence * a history of sensitivity to citalopram or escitalopram * use of other investigational drugs within 30 days of baseline or other psychotropic drugs or herbs within 14 days of baseline (28 days for fluoxetine) * need for concurrent psychotherapeutic intervention * pregnant or lactating females.

Keywords: ocd ssri escitalopram relapse
cyp2d6 genotype on the clinical effect of tamoxifen

Conditions: Breast Neoplasms; Tamoxifen; Genotype; CYP2D6

Summary: the purpose of this study is to investigate the impact of cyp2d6 genotype on the clinical effects of tamoxifen using with samples from prospective randomized multicenter study(astrra).


Eligibility criteria:
inclusion criteria: * the patient must sign the informed consent form. * the patient must sign the informed consent of genotype screening test. * the patient must be between 18 years old and 45 years old who can make a decision independently. * patients must have undergone excision of the primary breast mass, proven histologically to be invasive breast adenocarcinoma.(the type of mastectomy performed, number of axillary nodes removed, number of axillary nodes found positive, and tumor size must be included on the crfs. for patients who have more than one discrete tumor masses should be measured and reported on the crfs.) * patients must be within 3 months after the last cycle of chemotherapy. * patients must have the history of normal menstruation prior to the start of chemotherapy. * stage i, ii or iii * woman, less than or equal to 45 years of age * the test result of the estrogen receptor is positive. * who performance status 0, 1 or 2. * patients who were treated with cytotoxic chemotherapy in pre or post surgery. permissible prior chemotherapy; currently locally available and approved standard chemotherapy in the adjuvant or neoadjuvant setting: e.g., ac(doxorubicin/cyclophosphamide) followed by taxane, ac(doxorubicin/cyclophosphamide), ta(docetaxel/ doxorubicin), fac(5-fluorouracil/ doxorubicin / cyclophosphamide) or others. * adequate hematological function defined by hemoglobin 10g/dl, neutrophil count 1.5 x 10 9/l and platelets 100 x 10 9/l. * adequate hepatic function defined by ast and alt 2.5 x upper limit of normal. alkaline phosphatase 5 x upper limit of normal, unless bone metastases in the absence of liver disease. renal function adequate defined by creatinine \< 175 mmol/l. exclusion criteria: * the test result of the estrogen receptor is negative or unknown. * patients with the history of hysterectomy or oophorectomy. * sarcomas or squamous cell carcinomas of the breast are not eligible. * patients with malignancies(other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell/squamous cell carcinoma of the skin. * investigational drugs given within the previous 4 weeks. * patients with thrombocytopenia (platelets \< 100 x 10 9/l or on anti-coagulant therapy(contra-indicated due to risk of bleeding with i.m. injection of zoladex). * patients treated with cmf(cyclophosphamide/methotrexate/5-fluorouracil) as prior chemotherapy. * patients who are pregnant or lactating are ineligible.

Keywords: breast neoplasms tamoxifen genotype cyp2d6
a shared medical appointment intervention for quality of life improvement in pots

Conditions: Postural Orthostatic Tachycardia Syndrome

Summary: postural orthostatic tachycardia syndrome (pots) is a clinical syndrome encompassing a myriad of debilitating symptoms that does not have any fda approved drug therapies. we propose a shared medical appointment intervention where participants will learn lifestyle management therapies and integrative practices that may improve quality of life.


Eligibility criteria:
inclusion criteria: * patients with a physician diagnosis of pots exclusion criteria: * patients with uncontrolled psychiatric disease * patients with uncontrolled medical illness including recent myocardial infarction, stroke, and active malignancy * non-english speakers as the group intervention will be delivered in english * pregnant women
hospital wide roll-out of antimicrobial stewardship

Conditions: Bacterial Infections

Summary: dramatic increases in antibiotic utilization in hospitals continue to drive antibiotic resistance among hospital-acquired pathogens. however, 30-50% of the antibiotic use in hospitals is unnecessary or inappropriate. the infectious diseases society of america has published guidelines stating that all hospitals should develop an institutional program to enhance antimicrobial stewardship. at sunnybrook health sciences centre, an antibiotic stewardship audit-and-feedback intervention for all patients reaching their third or tenth day of broadspectrum antibiotic use in intensive care, resulted in a reduction of antibiotic use, antibiotic costs, and clostridium difficile infections in the intensive care unit. the investigators hypothesize that this intervention will result in similar benefits outside of the intensive care unit, and so expanded the intervention to non-icu medical and surgical wards. to increase the rigor of our program evaluation, the roll-out was conducted in a stepped-wedge randomized controlled design.


Eligibility criteria:
all patients admitted to the medical/surgical services will be included in statistical analysis of program evaluation. the inclusion/exclusion criteria below, just define who receives the antibiotic stewardship intervention on each service. inclusion criteria: * admitted to one of these services: general internal medicine, cardiology, nephrology, orthopedic surgery, neurosurgery, general surgery or trauma surgery * receiving 3rd or 10th day of treatment with one of the following antibiotics: * ceftriaxone, ceftazidime, piperacillin-tazobactam, ciprofloxacin, levofloxacin, meropenem, ertapenem, vancomycin exclusion criteria: * patient being followed by the infectious diseases consult service

Keywords: antibiotic stewardship. clostridium difficile infection. antibiotic resistance.
the air test: a new simple, non-invasive method to diagnose anesthesia-induced atelectasis

Conditions: Patients With ASA Status I-III Scheduled for Elective Surgery

Summary: anesthesia-induced atelectasis persist in the postoperative period but are not usually diagnosed because imaging techniques are required. the aim of the study is to determine whether the value of spo2≤96 while breathing room air (0.21 fio2) for 5 min, maneuver that we defined as the air test, was able to diagnose atelectasis in the postoperative period after a general anesthesia.


Eligibility criteria:
inclusion criteria: * asa i-iii * scheduled for elective surgery exclusion criteria: * age of \<18 years * pregnant women * previous lung resection * local-regional anesthesia * cardio-thoracic anesthesia * preoperative room air spo2 less than 97%
evaluation of characteristics of patients with nonsurgical complications after bariatric surgery and quality of life

Conditions: Obesity; Bariatric Surgery

Summary: retrospective study: analysis of characteristics of patients that were hospitalised with nonsurgical complications after bariatric surgery. cross-sectional study: to present and evaluate (clinical) parameters and quality of life measures of patients with nonsurgical complications after bariatric surgery compared to bariatric patients without hospitalisation for complications and obese patients.

retrospective study: the general objective is to describe and evaluate the characteristics of patients with nonsurgical complications after bariatric surgery based on parameters registered in the medical record. cross-sectional study: 1. primary objective: to evaluate how quality of life is perceived in patients hospitalised for nonsurgical complications after bariatric surgery compared to control groups through health-related quality of life (hrqol) questionnaires. 2. secondary objectives: to evaluate and compare (clinical) parameters and scoring on questionnaires about impact of weight, physical activity, anxiety and depression, impulsivity, alcohol use and eating behaviour for different bariatric and obese populations.

Eligibility criteria:
cross-sectional study patients hospitalised with non-surgical complications of bariatric surgery * inclusion criteria: * signed informed consent * patients underwent bariatric surgery * patients are hospitalised for nonsurgical complications of bariatric surgery at the endocrinology unit of uz leuven * exclusion criteria: * patients are not able to complete the questionnaires themselves * patients who do not understand dutch patients with bariatric surgery who were never hospitalised with non-surgical complications * inclusion criteria: * signed informed consent * patients underwent bariatric surgery * patients without history of hospitalisation for nonsurgical complications of bariatric surgery * exclusion criteria: * patients are not able to complete the questionnaires themselves * patients who do not understand dutch patients with obesity * inclusion criteria: * signed informed consent * patients visit the obesity clinic of uz leuven * exclusion criteria: * patients are not able to complete the questionnaires themselves * patients who do not understand dutch